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TheHIV-1genomeismalleableandadiﬃculttargettotvaccinateagainst.IthaslongbeenrecognisedthatcytotoxicTlymphocytes
and neutralising antibodies readily select for immune escape HIV variants. It is now also clear that NK cells can also select for
immune escape. NK cells force immune escape through both direct Killer-immunoglobulin-like receptor (KIR)-mediated killing
as well as through facilitating antibody-dependent cellular cytotoxicity (ADCC). These newer ﬁnding suggest NK cells and ADCC
responses apply signiﬁcant pressure to the virus. There is an opportunity to harness these immune responses in the design of more
eﬀective HIV vaccines.
1.Introduction
The human immunodeﬁciency virus (HIV-1) pandemic is
causingsubstantialmorbidityandmortalityacrosstheglobe,
particularly in developing countries. Antiretroviral drug
therapy for HIV is highly eﬀective in controlling disease;
however, eradication of HIV-1 is currently not feasible so
treatment is life long and is both expensive and leads to
considerable toxicity and drug resistance. A vaccine is widely
viewed as being essential to controlling the epidemic. Several
advanced eﬀorts to develop an eﬀective vaccine have failed
or shown only marginal eﬃcacy to date [1–4]. One of the
greatest challenges in developing a vaccine against HIV is to
overcome its ability to constantly mutate and escape anti-
HIV immune responses. This high mutation rate is a direct
result of the presence of the virus’ low ﬁdelity RNA poly-
merase enzyme as well as the high levels of recombination
it undergoes [5, 6].
A measure of the pressure immune responses apply is
through their ability to force viral mutations that result in
escape from immune recognition. Both CTLs and Nabs have
long been reported to select for immune escape variants
during the course of HIV-1 infection [7, 8]. Much eﬀort in
vaccine development centers on inducing broad and potent
CTL (cytotoxic T lymphocyte) and Nab (Neutralizing anti-
body) responses to conserved viral epitopes and restricting
opportunities for viral escape. However, it is now also recog-
nised other immune responses, such as antibody-dependent
cellularcytotoxicity(ADCC)andNKcells,selectforimmune
escape variants, suggesting additional immune responses
apply signiﬁcant pressure to the virus [9]. ADCC responses
mediated by eﬀector NK cells may be useful responses to
inducebyvaccination.Thispapersummarizescurrentthink-
ing on immune escape from anti-HIV immune responses.
2.CTLEscapeandtheRoadto
ReducedViralFitness
Immune escape from HIV was ﬁrst demonstrated for CTL-
based immunity in 1991 [8]. Considerable work since then
has shown CTL escape is typically regulated by the eﬀect
of the escape mutation on comparative viral ﬁtness, a
complex parameter illustrating the overall contribution of
all mutation-related advantages and losses (Table 1). Even
thoughtheevasionofimmuneresponsespresentedbyescape
mutations presents a deﬁnite ﬁtness beneﬁt to the virus, the
HIV-1 proteome is not inﬁnitely malleable hence the same2 Advances in Virology
Table 1: Key escape papers.
Immune
response Hypothesis Result Ref.
CTL based
HLA-B∗57/B∗5801 CTL escape
mutations in Gag impacts viral
replication in vivo
Reductions in relative replication
capacity reduce “viral ﬁtness” [20]
CTL escape mutations in Env do not
result in reduced viral ﬁtness
Escape mutations within Env-speciﬁc
CTL are epitopes evident but no
correlation with reduced SIV replication
[25]
Step HIV-1 vaccine trial exerts selective
CTL pressure on HIV-1
Extended sequence divergence for vaccine
recipients who become infected suggests
vaccine-induced CTL imparted
signiﬁcant immune pressure
Gag-84 most signiﬁcant signature site
[36]
Nab based
Evolving “glycan shield” mechanism
prevents Nab binding
Env gene mutations in escape virus sparse
Escape mutations did not map to known
epitopes
Eﬃcient neutralization requires potent,
high titres
[54]
Continual selection of Nab escape
variants occurs
All previous viral isolates, but not
concurrent isolate, are recognised by
concurrent Nab
[7]
Passive transfer of human neutralizing
monoclional antibodies delays HIV-1
rebound post-antiretroviral therapy
2G12 monoclonal was crucial for
transient in vivo eﬀect of Nab cocktail but
immune escape resulted
[55]
ADCC based
Immune pressure from HIV-speciﬁc
ADCC results in immune-escape variants
ADCC causes escape in multiple epitopes
and evolves over timeADCC antibodies
forcing immune escape can be
non-eutralizing
[9]
NK cells apply immunological pressure
on HIV-1 through direct killing of
infected cells
HIV-1 selects KIR2DL2+ virus mutations
that result in reduced antiviral activity of
NK cells
[85]
mutations can result in ﬁtness costs. Some CTL immune
escape variants have reduced replicative capacity of the virus
(reduced “ﬁtness”) that slows the progression of disease
[10, 11]. Studies have demonstrated that certain viruses
composed of immune escape mutations are associated with
lower viral loads within subjects [12, 13]. It has also been
suggested that the rate of viral escape likely reﬂects the
strength of the immune pressure and the ﬁtness cost of
the mutant virus [14] .F i t n e s sc o s t sa r em o s td r a m a t i c a l l y
illustrated in vivo by the reversion of transmitted escape
mutations during acute and early HIV-1 infection [15–19].
S e v e r a lC T Le s c a p em u t a t i o n sh a v eb e e nc o n ﬁ r m e d
to disrupt normal virus protein structure and/or function
[20–23]. More than half of deleterious escape mutations
have been veriﬁed in the relatively conserved Gag protein,
whereas Troyer et al. [24] recently presented that CTL escape
mutations in Env did not commonly transfer an associated
ﬁtness cost and indeed in a number of cases strengthened
competitive viral ﬁtness. This result is consistent with the
lack of reversion of Env CTL escape mutations in vivo [25,
26]. Macaque and human studies have also demonstrated
that escape from T-cell immunity leads to ongoing HIV or
SIV infection [27]. The latest investigation of the eﬀect on
viral replication of twenty CTL escape mutations in Gag epi-
topesestablishedonlythreeescapemutationsthatresultedin
substantialreductionsinviralreplicationcapacity,indicating
that high-cost escape mutations are rather rare [28]. More
importantly, these three highly eﬀective CTL escape muta-
tions appeared in epitopes primarily targeted during acute
infection by protective HLA class I alleles [29]. This demon-
strates that the protection allowed by certain HLA class I
alleles may arise because the barrier to viral escape in the tar-
getedepitopeishighleadingtoeithermaintenanceofadom-
inant and eﬀective CD8+ T-cell response, and/or attenuation
of virus replication from selection of high-cost escape muta-
tions.ExaminationofvirusesderivedfromHIV-1controllers
(individuals who maintain long-term control of HIV-1 vire-
mia) reveal evidence of a role for rare or novel CTL escape-
associated ﬁtness costs in control of HIV-1 replication [30–
33].
CTL responses and the immune escape variants induced
are also important in HIV transmission scenarios. Two
recent reports detail early clinical correlates related with the
transmission of viruses expressing a number of CTL escape
mutations known to weaken in vitro replication capacity
[12, 34]. As the transmitted escape mutations revert to wild
type [23], these enhanced results associated with such trans-
missions have been perceived to decline and the long-term
clinical outcome of these transient eﬀects remains unforesee-
able. With improved characterization of the virology of acuteAdvances in Virology 3
HIV-1 infection diﬀerences in founder virus, replication
compared with viral escape strains caused by dominant
CD8+ T-cell responses is becoming easier to model. The dis-
tinctions between the founder virus and viral escape strains
maycontributetoobservedvariabilityintheimmunecontrol
ofHIV-1replication,whichmaybecausedbycarry-overmu-
tations and variation in the rate of escape related to ﬁtness
costs from key CD8+ T-cell responses, in return inﬂuencing
set-point viral load and early clinical disease course [35].
Elite control of viral replication may in part be due to the
transmission of a virus attenuated by accumulated carryover
mutations from hosts with such principal CD8+ T-cell
responses to escape associated epitopes resulting in high ﬁt-
ness costs. Rolland et al. recently illustrated the ﬁrst evi-
dence of selective pressure from vaccine-induced T-cell re-
sponses on HIV-1 infection by analyzing HIV-1 genome
sequences from 68 volunteers who participated in the STEP
Adenovirus-vector HIV-1 vaccine eﬃcacy trial [36]. Com-
parison of T-cell epitopes in the founder sequences to epit-
opes in the vaccine distinguished greater breadth for sequen-
ces from vaccine recipients than from placebo recipients,
suggestingthevaccineimpartedimportant immune pressure
to the selection of the infecting isolates. Vaccine-induced
ﬁtness-impaired virus could, if suﬃciently potent, translate
into a reduction in viral loads and attenuation of disease
progression.
3. The Great Escapefrom
Neutralizing Antibodies
Considerable data exist illustrating the eﬀect of neutralizing
antibodies in protecting against HIV-1 infection in vitro [37,
38]a n din vivo using animal models [39–46]. Although anti-
bodies are made to all HIV proteins within a few weeks, only
those to the envelope glycoproteins can prevent or neutralize
HIVinfection.Theseneutralizingantibodies(Nab)takecon-
siderably longer to develop than binding antibodies, gen-
erally months to years [47]. HIV-infected subjects almost
always develop Nab to their own virus (autologous neu-
tralization), although Nabs typically respond to earlier viral
isolates, with the subject’s contemporaneous virus having
escaped. Some subjects eventually develop Nabs able to
cross-neutralize additional viruses (heterologous neutraliza-
tion), but their concurrent virus is still usually escaped from
their autologous Nab. This highlights many of the diﬃculties
involved in controlling HIV replication by Nab and the abil-
ity of HIV to escape antibody pressure through a process of
genetic change [38]. The envelope gene presents the highest
ratio of genetic diversity, most likely as a direct result of Nab
pressure. However, for the virus to remain infective, portions
of the envelope gene that encode regions essential for func-
tional activity, such as CD4 and coreceptor binding, need
to be conserved, and hence escape from Env Nabs probably
results in little ﬁtness cost. Individuals who do develop out-
standing Nab responses generally have antibodies directed
towards such crucial functional regions [48]. Long-term
nonprogressors who have remained symptom-free for many
years without antiretroviral therapy in general have broader
and more potent responses compared to persons who show
progressive disease [49–53].
Escape from neutralizing antibody responses often in-
volves serial changes in glycosylation patterns and small
insertions and deletions [7]. Richman and colleagues found
that 9 of 12 untreated patients with detectable neutraliz-
ing antibody had the highest neutralising antibody titer
towards against the baseline virus (month 0) whereas only
three subjects showed higher titers of neutralizing antibody
against viruses that appeared later in infection [7]. Wei
and colleagues clearly illustrated the inhibition of HIV-
1 by Nabs when successive populations of resistant virus
were completely substituted by neutralization-sensitive virus
[54]. Furthermore, they showed escape virus contained
infrequent mutations in the env gene, generally mapped
to unknown neutralization epitopes, and involved changes
mainly in N-linked glycosylation sites. This pattern of escape
led to the hypothesis of an evolving “glycan shield” mech-
anism of neutralization escape which selected diﬀerences
in glycan packing preventing Nab binding but not receptor
binding. Mutational substitution assays showed that Nab-
selected alterations in glycosylation presented escape from
both autologous antibody and epitope-speciﬁc monoclonal
antibodies. Thus a new mechanism was presented contribut-
ing to HIV-1 persistence in the presence of an antibody
repertoire.
Viral escape regardless of the presence of neutralizing
antibodies could demonstrate either that antibodies were
ineﬀective in vivo, in which case antibody-sensitive viral
strains would remain, or otherwise that the virus escaped
the pressure applied by the antibody. Trkola et al. illustrated
that passive transfer of Nabs in humans with established
HIV resulted in immune escape by comparing the inhibitory
activity of 3 monoclonal Nabs (2F5, 4E10 and 2G12) against
virus isolates derived before the passive transfer trial and to
sequential isolates after antibody treatment [55]. There was
a strong association between development of 2G12-resistant
viral strains and emergence of escape mutants to this
antibody, failure to respond to treatment and loss of viremia
control. While evidence of virus escape implies Nab selective
pressure to a certain extent [7, 54, 55], it has been speculated
thatpostinfectionNabscouldexertonlyalimitedsuppressive
eﬀect on primary HIV replication [45, 56, 57]. Prevention
of primary SIV or SHIV replication in monkeys by passive
Nab immunization prior to or very early after infection
is achievable [40, 58–60]. Taken together, this suggests that
HIVcontrolbypotentNabsismostlikelytobeeﬀectiveprior
to infection. Immune escape is likely to compromise the role
of Nabs after infection is already manifested.
The role of neutralizing antibodies in preventing or
limiting HIV-1 infection is becoming clearer with a better
understanding of the structure of the envelope glycoprotein
as well as passive immunization studies in animals showing
thatantibodiescanindeedcontrolinfection.Furtherinsights
into neutralization-sensitive epitopes on the envelope glyco-
proteinareneededthatwillenableustodesignbettervaccine
immunogens in vaccines. Ultimately this should allow the
ability to induce neutralizing antibodies in conjunction with
additional antibody-mediated protective mechanisms such4 Advances in Virology
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Figure 1: HIV-speciﬁc immune responses force immune escape. The mechanism of immune pressure applied by Cytotoxic T lymphocytes
(a), neutralizing antibodies (b), and ADCC antibodies (1) is illustrated. Escape from immune responses shows results once free virus (Nab
responses) or viral particles are presented either via the MHC class pathway (CTL responses) or possibly on the surface of the infected cell
by virus budding (ADCC).
as antibody-dependent cell-mediated cytotoxicity (ADCC)
in the ﬁght against HIV.
4. Escape from ADCC
Sequencing single HIV genomes from subjects with acute
HIV-1 infection reveals that multiple mutations are acquired
during the ﬁrst months of infection and most align with
sites of CTL or Nab escape mutations [61, 62]. However,
some mutations do not clearly map to known sites of CTL
or Nab escape, suggesting there may be other immune
responses, such as ADCC responses, suﬃciently potent to
select immune escape strains. ADCC antibodies bind to viral
antigens on the surface of infected cells and engage Fc recep-
tors on innate immune cells such as NK cells, macrophages,
and neutrophils, which in turn lyse the HIV-infected cell
(Figure 1(c)).
ADCC is an area relatively poorly explored in HIV
immunology in recent years. Very few ADCC epitopes have
been identiﬁed to date within HIV. The majority of these
identiﬁed ADCC epitopes are within Env glycoproteins,
gp120 [63–66]a n dg p 4 1[ 67–69], Tat [70]a n dN e f[ 71, 72].
Several recent studies in both humans and macaques
are now suggesting that ADCC antibodies can be eﬀective
in controlling HIV or SIV [4, 73, 74]. The potent immune
pressure that can be applied by HIV-speciﬁc ADCC anti-
bodies has only recently been brought into sharper focus.
Importantly, Hessell and colleagues performed experiments
on Nab mutated in the Fc region, which showed a reduced
ability of the Nab to mediate killing of infected cells in vitro.
When they administered the mutant (Fc defective) Nab to
macaques, they were also markedly reduced in their ability
to prevent SHIV infection [73]. It perhaps should be no
surprise that ADCC antibodies are also implicated in viral
escape as the HIV genome is able to make multiple changes
to avoid CTL, Nab, and antiretroviral drug pressure.
ADCC responses forcing immune escape had until
recently not previously been demonstrated. Demonstrating
v i r a le s c a p ef r o mA D C Cr e s p o n s e sw o u l ds t r o n g l ys u g g e s t
that ADCC responses exert signiﬁcant pressure on the
immune system [75]. Stratov et al. described a novel assay
whichallowedthemapping ofaseries of HIV-speciﬁcADCC
epitopes in subjects infected with HIV, using a set of con-
sensus HIV peptides [76]. The identiﬁed epitopes within the
subjects HIV strains were then further cloned and sequenced
across the relevant epitopes and analyzed as to whether their
ADCC responses were able to recognize their own virus
strain. Evidence of immune escape was found against mul-
tiple HIV-speciﬁc ADCC epitopes studied in the Env protein
of HIV-1 [9]. Evolution of escape over time was detected in
contemporary plasma samples, which diﬀered signiﬁcantly
from initial viral sequences at areas targeted by ADCC.
ADCCantibodyresponsesaregenerallythoughttotarget
viral surface proteins presented on the surface of infected
cells. Our group has also identiﬁed ADCC responses to viral
peptides derived from internal HIV-1 proteins such as Vpu
and Pol [75, 76]. Interestingly, we also identiﬁed possible
immune escape to an epitope of the highly conserved protein
Pol [77]. It is not immediately apparent how these epitopes
would be presented on the surface of cells to ADCC antibod-
ies and force viral escape and much more work needs to beAdvances in Virology 5
donetodeﬁnewhetherADCCantibodiestointernalproteins
can recognize HIV-infected cells in vitro. We speculate that
it may also be possible that ADCC recognition of viral
debris on the surface of healthy neighboring cells may trigger
noncytolytic activity from NK cells that could limit HIV-1
spread in a local environment. Such a mechanism would also
be susceptible to immune escape.
Using ADCC peptide epitopes and an NK-cell activation
assay,thehypothesisthatADCCplaysamajorpartintheim-
mune response against HIV was conﬁrmed. This work likely
underestimates the number of ADCC epitopes targeted by
each HIV+ subject, since linear epitopes are readily mapped
and dissected and consensus B overlapping peptides are
used for screening. Conformational ADCC antibodies are
likely to elicit escape also but to map such responses and
identify escape patterns will be more diﬃcult and require
large numbers of mutant whole Env proteins.
The partial eﬃcacy shown by the recently reported
canarypox prime/protein boost vaccine trial conducted in
Thailand [78] could possibly be associated with ADCC anti-
bodies.Recentconferencepresentationshavecorrelatednon-
neutralizing antibody responses to vaccine eﬃcacy, although
much work remains to be done to understand this fully [79].
It is conceivable, by analogy with results on CTL responses in
the STEP trial [36], that vaccinated subjects in the Thai trial
who still became infected may have become infected with
HIV variants already “preescaped” at the ADCC responses
induced by their vaccination.
ADCC-forced mutations could theoretically incur some
“ﬁtness cost” to viral replicative capacity, similar to that
observed for CTL escape variants [12]. Constructing repli-
cating viruses with ADCC-induced mutations will allow
testing of this hypothesis. More potent ADCC antibodies are
likely to target conserved or functional domains of viral pro-
teins. The Env protein is highly diverse and readily escapes
CTL and Nab responses with apparent minimal ﬁtness costs
[7, 24, 26, 80]. It is possible that any ﬁtness cost of ADCC
escapeinEnvcouldalsobesmall.ADCCantibodiestargeting
conserved non-Env proteins such as Vpu and Pol may be
more potent, although it needs to be assessed whether these
antibodies recognize HIV-infected cells as noted above. It is
also likely that compensatory mutations may emerge which
repair any ﬁtness cost of primary mutations [81]. Further
studies on the patterns of ADCC escape and the speciﬁc
cellular components involved in ADCC should allow a ﬁner
understanding of how to either limit ADCC escape or force
larger ﬁtness costs.
Natural killer (NK) cells are the key eﬀector cells medi-
ating ADCC function. Virally infected cells are identiﬁed
through a range of activating and inhibitory receptors [82]
as well as both activating and inhibitory killer immunoglob-
ulin-like receptors (KIRs) [83, 84]. Alter and colleagues
recently clearly demonstrated that NK cells can directly me-
d i a t ea n t i v i r a li m m u n ep r e s s u r ein vivo in humans [85].
They showed that the binding of inhibitory KIRs to HIV-1-
infectedCD4+Tcellsisampliﬁedandtheantiviralactivityof
KIR-positive NK cells is diminished by KIR-associated HIV-
1 sequence polymorphisms. Similar to immune pressure ap-
plied by virus-speciﬁc T cells and neutralizing antibodies, it
seems plausible to state that KIR-positive NK cells can place
immunological pressure on HIV-1 and that the virus can
evade such NK-cell-mediated immune pressure by selecting
for sequence polymorphisms.
5. Conclusions
CTL and Nab immune responses are pivotal drivers in
immune escape and viral variability. It is now clear that the
role of NK cells in viral selection, both through direct killing
and ADCC mechanisms, is likely to have been previously
underestimated. Other eﬀector cells of the innate immune
system, including macrophages and neutrophils, may also be
importantindrivingHIVevolution.Evidenceofthepressure
applied by ADCC antibodies now provides challenges to
inducingthemosteﬀectiveADCCantibodiesbyvaccination.
A better understanding of the immune responses to HIV is
required to fully harness the potential of a vaccine to both
prevent viral entry and ongoing infection.
References
[1] E. Iaccino, M. Schiavone, G. Fiume, I. Quinto, and G. Scala,
“The aftermath of the Merck’s HIV vaccine trial,” Retrovirol-
ogy, vol. 5, article 56, 2008.
[ 2 ]J .H .K i m ,S .R e r k s - N g a r m ,J .L .E x c l e r ,a n dN .L .M i c h a e l ,
“HIV vaccines: lessons learned and the way forward,” Current
Opinion in HIV and AIDS, vol. 5, no. 5, pp. 428–434, 2010.
[3] N. A. Wilson and D. I. Watkins, “Is an HIV vaccine possible?”
Brazilian Journal of Infectious Diseases, vol. 13, no. 4, pp. 304–
310, 2009.
[4] S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan et al., “Vacci-
nation with ALVAC and AIDSVAX to prevent HIV-1 infection
in Thailand,” New England Journal of Medicine, vol. 361, no.
23, pp. 2209–2220, 2009.
[ 5 ]E .S .S v a r o v s k a i a ,S .R .C h e s l o c k ,W .H .Z h a n g ,W .S .H u ,
and V. K. Pathak, “Retroviral mutation rates and reverse tran-
scriptase ﬁdelity,” Frontiers in Bioscience, vol. 8, pp. d117–
d134, 2003.
[6] A. Onafuwa-Nuga and A. Telesnitsky, “The remarkable fre-
quency of human immunodeﬁciency virus type 1 genetic
recombination,” Microbiology and Molecular Biology Reviews,
vol. 73, no. 3, pp. 451–480, 2009.
[7] D. D. Richman, T. Wrin, S. J. Little, and C. J. Petropoulos,
“Rapid evolution of the neutralizing antibody response to
HIV type 1 infection,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 100, no. 7, pp.
4144–4149, 2003.
[8] R. E. Phillips, S. Rowland-Jones, D. F. Nixon et al., “Human
immunodeﬁciency virus genetic variation that can escape
cytotoxic T cell recognition,” Nature, vol. 354, no. 6353, pp.
453–459, 1991.
[ 9 ]A .W .C h u n g ,G .I s i t m a n ,M .N a v i se ta l . ,“ I m m u n ee s c a p e
from HIV-speciﬁc antibody-dependent cellular cytotoxicity
(ADCC) pressure,” Proceedings of the National Academy of Sci-
encesoftheUnitedStatesofAmerica,vol.108,no.18,pp.7505–
7510, 2011.
[10] C. S. Fernandez, I. Stratov, R. De Rose et al., “Rapid viral es-
cape at an immunodominant simian-human immunodeﬁ-
ciency virus cytotoxic T-lymphocyte epitope exacts a dramatic
ﬁtness cost,” Journal of Virology, vol. 79, no. 9, pp. 5721–5731,
2005.6 Advances in Virology
[ 1 1 ]A .J .L e s l i e ,K .J .P f a ﬀerott, P. Chetty et al., “HIV evolution:
CTL escape mutation and reversion after transmission,”
Nature Medicine, vol. 10, no. 3, pp. 282–289, 2004.
[12] P. A. Goepfert, W. Lumm, P. Farmer et al., “Transmission of
HIV-1 Gag immune escape mutations is associated with re-
duced viral load in linked recipients,” Journal of Experimental
Medicine, vol. 205, no. 5, pp. 1009–1017, 2008.
[13] T. M. Allen and M. Altfeld, “Crippling HIV one mutation at
a time,” Journal of Experimental Medicine, vol. 205, no. 5, pp.
1003–1007, 2008.
[14] S. J. Kent, C. S. Fernandez, C. J. Dale, and M. P. Davenport,
“Reversion of immune escape HIV variants upon transmis-
sion: insights into eﬀective viral immunity,” Trends in Micro-
biology, vol. 13, no. 6, pp. 243–246, 2005.
[ 1 5 ]A .J .L e s l i e ,K .J .P f a ﬀerott, P. Chetty et al., “HIV evolution:
CTL escape mutation and reversion after transmission,”
Nature Medicine, vol. 10, no. 3, pp. 282–289, 2004.
[16] J. Herbeck, M. Rolland, W. Deng, A. Collier, and J. Mullins, in
AIDS Vaccine, A. L. Ross, Ed., vol. 6, Paris, France, 2009.
[17] N.Goonetillek e,M.K.P .Liu,J .F .Salazar -Gonzalezetal.,“The
ﬁrst T cell response to transmitted/founder virus contributes
to the control of acute viremia in HIV-1 infection,” Journal of
Experimental Medicine, vol. 206, no. 6, pp. 1253–1272, 2009.
[18] M. Kearney, F. Maldarelli, W. Shao et al., “Human immunod-
eﬁciency virus type 1 population genetics and adaptation in
newly infected individuals,” Journal of Virology, vol. 83, no. 6,
pp. 2715–2727, 2009.
[19] B. Li, A. D. Gladden, M. Altfeld et al., “Rapid reversion of se-
quence polymorphisms dominates early human immunodeﬁ-
ciency virus type 1 evolution,” Journal of Virology, vol. 81, no.
1, pp. 193–201, 2007.
[ 2 0 ]C .L .B o u t w e l l ,C .F .R o w l e y ,a n dM .E s s e x ,“ R e d u c e dv i r a l
replication capacity of human immunodeﬁciency virus type
1 subtype C caused by cytotoxic-T-lymphocyte escape muta-
tions in HLA-B57 epitopes of capsid protein,” Journal of
Virology, vol. 83, no. 6, pp. 2460–2468, 2009.
[21] M. A. Brockman, A. Schneidewind, M. Lahaie et al., “Escape
andcompensationfromearlyHLA-B57-mediatedcytotoxicT-
lymphocyte pressure on human immunodeﬁciency virus type
1 Gag alter capsid interactions with cyclophilin A,” Journal of
Virology, vol. 81, no. 22, pp. 12608–12618, 2007.
[22] A. Schneidewind, M. A. Brockman, J. Sidney et al., “Structural
and functional constraints limit options for cytotoxic T-
lymphocyte escape in the immunodominant HLA-B27-re-
stricted epitope in human immunodeﬁciency virus type 1
capsid,” Journal of Virology, vol. 82, no. 11, pp. 5594–5605,
2008.
[23] H. Crawford, W. Lumm, A. Leslie et al., “Evolution of HLA-
B 5703 hiv-1 escape mutations in HLA-B 5703-positive indi-
viduals and their transmission recipients,” Journal of Experi-
mental Medicine, vol. 206, no. 4, pp. 909–921, 2009.
[24] R. M. Troyer, J. McNevin, Y. Liu et al., “Variable ﬁtness impact
of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL)
response,” PLoS Pathogens, vol. 5, no. 4, 2009.
[25] V. Peut and S. J. Kent, “Substantial envelope-speciﬁc CD8 T-
cell immunity fails to control siv disease,” Virology, vol. 384,
no. 1, pp. 21–27, 2009.
[26] V. Peut and S. J. Kent, “Utility of human immunodeﬁciency
virus type 1 envelope as a T-cell immunogen,” Journal of Virol-
ogy, vol. 81, no. 23, pp. 13125–13134, 2007.
[27] D. H. Barouch, J. Kunstman, M. J. Kuroda et al., “Eventual
AIDS vaccine failure in a rhesus monkey by viral escape from
cytotoxic T lynphocytes,” Nature, vol. 415, no. 6869, pp. 335–
339, 2002.
[28] C. L. Boutwell, A. Schneidewind, Z. Brumme et al., “P09-19
LB. CTL escape mutations in gag epitopes restricted by
protective HLA class I alleles cause substantial reductions in
viral replication capacity,” Retrovirology,v o l .6 ,n o .3 ,a r t i c l e
1742, p. P399, 2009.
[29] H. Streeck, J. S. Jolin, Y. Qi et al., “Human immunodeﬁciency
virus type 1-speciﬁc CD8+ T-cell responses during primary
infection are major determinants of the viral set point and loss
of CD4+ Tc e l l s , ”Journal of Virology, vol. 83, no. 15, pp. 7641–
7648, 2009.
[30] T. Miura, M. A. Brockman, C. J. Brumme et al., “Genetic char-
acterization of human immunodeﬁciency virus type 1 in elite
controllers: lack of gross genetic defects or common amino
acid changes,” Journal of Virology, vol. 82, no. 17, pp. 8422–
8430, 2008.
[ 3 1 ]T .M i u r a ,C .J .B r u m m e ,M .A .B r o c k m a ne ta l . ,“ H L A - a s s o -
ciated viral mutations are common in human immunodeﬁ-
ciency virus type 1 elite controllers,” Journal of Virology, vol.
83, no. 7, pp. 3407–3412, 2009.
[32] T.Miura,M.A.Brockman,A.Schneidewindetal.,“HLA-B57/
B∗5801 human immunodeﬁciency virus type 1 elite con-
trollers select for rare gag variants associated with reduced
viral replication capacity and strong cytotoxic T-lymphotye
recognition,” Journal of Virology, vol. 83, no. 6, pp. 2743–2755,
2009.
[33] T. Miura, M. A. Brockman, Z. L. Brumme et al., “HLA-asso-
ciated alterations in replication capacity of chimeric NL4-3
viruses carrying gag-protease from elite controllers of human
immunodeﬁciency virus type 1,” Journal of Virology, vol. 83,
no. 1, pp. 140–149, 2009.
[34] D. R. Chopera, Z. Woodman, K. Mlisana et al., “Transmission
of HIV-1 CTL escape variants provides HLA-mismatched
recipients with a survival advantage,” PLoS Pathogens, vol. 4,
no. 3, Article ID e1000033, 2008.
[35] C. L. Boutwell, M. M. Rolland, J. T. Herbeck, J. I. Mullins,
and T. M. Allen, “Viral evolution and escape during acute
HIV-1 infection,” The Journal of Infectious Diseases, vol. 202,
supplement, pp. S309–S314, 2010.
[36] M. Rolland, S. Tovanabutra, A. C. Decamp et al., “Genetic
impact of vaccination on breakthrough HIV-1 sequences from
the STEP trial,” Nature Medicine, vol. 17, no. 3, pp. 366–372,
2011.
[37] N. L. Haigwood and L. Stamatatos, “Role of neutralizing
antibodies in HIV infection,” AIDS, vol. 17, supplement, pp.
S67–S71, 2003.
[ 3 8 ]P .W .P a r r e n ,J .P .M o o r e ,D .R .B u r t o n ,a n dQ .J .S a t t e n t a u ,
“The neutralizing antibody response to HIV-1: viral evasion
and escape from humoral immunity,” AIDS, vol. 13, supple-
ment, pp. S137–162, 1999.
[39] T. W. Baba, V. Liska, R. Hofmann-Lehmann et al., “Human
neutralizing monoclonal antibodies of the IgG1 subtype pro-
tect against mucosal simian-human immunodeﬁciency virus
infection,” Nature Medicine, vol. 6, no. 2, pp. 200–206, 2000.
[40] J. R. Mascola, G. Stiegler, T. C. Vancott et al., “Protection
of macaques against vaginal transmission of a pathogenic
HIV- 1/SIV chimeric virus by passive infusion of neutralizing
antibodies,” Nature Medicine, vol. 6, no. 2, pp. 207–210, 2000.
[41] J. R. Mascola, M. G. Lewis, G. Stiegler et al., “Protection of
macaques against pathogenic simian/human immunodeﬁ-
ciency virus 89.6PD by passive transfer of neutralizing anti-
bodies,” Journal of Virology, vol. 73, no. 5, pp. 4009–4018,
1999.
[42] R. S. Veazey, R. J. Shattock, M. Pope et al., “Prevention of virus
transmission to macaque monkeys by a vaginally appliedAdvances in Virology 7
monoclonal antibody to HIV-1 gp120,” Nature Medicine, vol.
9, no. 3, pp. 343–346, 2003.
[ 4 3 ] N .L .H a i g w o o d ,D .C .M o n t e ﬁ o r i ,W .F .S u t t o ne ta l . ,“ P a s s i v e
immunotherapy in simian immunodeﬁciency virus-infected
macaques accelerates the development of neutralizing anti-
bodies,” Journal of Virology, vol. 78, no. 11, pp. 5983–5995,
2004.
[44] P.W.H.I.Parren,P.A.Marx,A.J.Hesselletal.,“Antibodypro-
tects macaques against vaginal challenge with a pathogenic R5
simian/human immunodeﬁciency virus at serum levels giving
complete neutralization in vitro,” Journal of Virology, vol. 75,
no. 17, pp. 8340–8347, 2001.
[45] P. Poignard, R. Sabbe, G. R. Picchio et al., “Neutralizing anti-
bodies have limited eﬀects on the control of established HIV-1
infection in vivo,” Immunity, vol. 10, no. 4, pp. 431–438, 1999.
[46] M. C. Gauduin, P. W. H. I. Parren, R. Weir, C. F. Barbas, D. R.
Burton,andR.A.Koup,“Passive immunizationwith ahuman
monoclonal antibody protects hu-PBL- SCID mice against
challenge by primary isolates of HIV-1,” Nature Medicine, vol.
3, no. 12, pp. 1389–1393, 1997.
[47] C. Moog, H. J. A. Fleury, I. Pellegrin, A. Kirn, and A. M.
Aubertin, “Autologous and heterologous neutralizing anti-
body responses following initial seroconversion in human
immunodeﬁciency virus type 1-infected individuals,” Journal
of Virology, vol. 71, no. 5, pp. 3734–3741, 1997.
[48] A. Pinter, W. J. Honnen, S. C. Kayman, O. Trochev, and Z. Wu,
“PotentneutralizationofprimaryHIV-1isolatesbyantibodies
directedagainstepitopespresentintheV1/V2domainofHIV-
1 gp120,” Vaccine, vol. 16, no. 19, pp. 1803–1811, 1998.
[49] Y.Cao,L.Qin,L.Zhang,J.Safrit,andD.D.Ho,“Virologicand
immunologic characterization of long-term survivors of hu-
man immunodeﬁciency virus type 1 infection,” New England
Journal of Medicine, vol. 332, no. 4, pp. 201–208, 1995.
[ 5 0 ]P .C a r o t e n u t o ,D .L o o i j ,L .K e l d e r m a n s ,F .D eW o l f ,a n dJ .
Goudsmit, “Neutralizing antibodies are positively associated
with CD4+ T-cell counts and T-cell function in long-term
AIDS-free infection,” AIDS, vol. 12, no. 13, pp. 1591–1600,
1998.
[51] D. C. Monteﬁori, G. Pantaleo, L. M. Fink et al., “Neutralizing
and infection-enhancing antibody responses to human im-
munodeﬁciency virus type 1 in long-term nonprogressors,”
Journal of Infectious Diseases, vol. 173, no. 1, pp. 60–67, 1996.
[52] A. K. Pilgrim, G. Pantaleo, O. J. Cohen et al., “Neutralizing
antibody responses to human immunodeﬁciency virus type
1 in primary infection and long-term—nonprogressive infec-
tion,” Journal of Infectious Diseases, vol. 176, no. 4, pp. 924–
932, 1997.
[53] Y. J. Zhang, C. Fracasso, J. R. Fiore et al., “Augmented serum
neutralizing activity against primary human immunodeﬁ-
ciency virus type 1 (HIV-1) isolates in two groups of HIV-
1- infected long-term nonprogressors,” Journal of Infectious
Diseases, vol. 176, no. 5, pp. 1180–1187, 1997.
[54] X. Wei, J. M. Decker, S. Wang et al., “Antibody neutralization
and escape by HIV-1,” Nature, vol. 422, no. 6929, pp. 307–312,
2003.
[55] A. Trkola, H. Kuster, P. Rusert et al., “Delay of HIV-1 rebound
after cessation of antiretroviral therapy through passive trans-
fer of human neutralizing antibodies,” Nature Medicine, vol.
11, no. 6, pp. 615–622, 2005.
[56] N. L. Haigwood, A. Watson, W. F. Sutton et al., “Passive im-
muneglobulintherapyintheSIV/macaquemodel:earlyinter-
ventisn can alter disease proﬁle,” Immunology Letters, vol. 51,
no. 1-2, pp. 107–114, 1996.
[57] Y. Nishimura, T. Igarashi, N. L. Haigwood et al., “Transfer of
neutralizing IgG to macaques 6 h but not 24 h after SHIV
infection confers sterilizing protection: implications for HIV-
1 vaccine development,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 100, no. 25, pp.
15131–15136, 2003.
[58] H. Yamamoto, M. Kawada, A. Takeda, H. Igarashi, and T.
Matano, “Post-infection immunodeﬁciency virus control by
neutralizing antibodies,” PloS One, vol. 2, no. 6, p. e540, 2007.
[59] A. J. Hessell, P. Poignard, M. Hunter et al., “Eﬀective, low-titer
antibody protection against low-dose repeated mucosal SHIV
challenge in macaques,” Nature Medicine, vol. 15, no. 8, pp.
951–954, 2009.
[60] A. J. Hessell, E. G. Rakasz, D. M. Tehrani et al., “Broadly neu-
tralizingmonoclonalantibodies2F5and4E10directedagainst
the human immunodeﬁciency virus type 1 gp41 membrane-
proximal external region protect against mucosal challenge by
simian-human immunodeﬁciency virus SHIVBa-L,” Journal
of Virology, vol. 84, no. 3, pp. 1302–1313, 2010.
[61] N.Goonetilleke,M.K.P.Liu,J.F.Salazar-Gonzalezetal.,“The
ﬁrst T cell response to transmitted/founder virus contributes
to the control of acute viremia in HIV-1 infection,” Journal of
Experimental Medicine, vol. 206, no. 6, pp. 1253–1272, 2009.
[62] S. Jain, A. J. Patrick, and K. L. Rosenthal, “Multiple tandem
copies of conserved gp41 epitopes incorporated in gag virus-
like particles elicit systemic and mucosal antibodies in an
optimized heterologous vector delivery regimen,” Vaccine, vol.
28, no. 43, pp. 7070–7080, 2010.
[63] O. Alsmadi, R. Herz, E. Murphy, A. Pinter, and S. A. Tilley, “A
novel antibody-dependent cellular cytotoxicity epitope in
gp120 is identiﬁed by two monoclonal antibodies isolated
from a long-term survivor of human immunodeﬁciency virus
type 1 infection,” Journal of Virology, vol. 71, no. 2, pp. 925–
933, 1997.
[ 6 4 ] R .A .K o u p ,J .E .R o b i n s o n ,Q .V .N g u y e ne ta l . ,“ A n t i b o d y - d e -
pendent cell-mediated cytotoxicity directed by a human mon-
oclonal antibody reactive with gp120 of HIV-1,” AIDS, vol. 5,
no. 11, pp. 1309–1314, 1991.
[65] O. Alsmadi and S. A. Tilley, “Antibody-dependent cellular
cytotoxicity directed against cells expressing human immun-
odeﬁciency virus type 1 envelope of primary or laboratory-
adapted strains by human and chimpanzee monoclonal anti-
bodies of diﬀerent epitope speciﬁcities,” Journal of Virology,
vol. 72, no. 1, pp. 286–293, 1998.
[66] K. Broliden, A. Von Gegerfelt, C. Persson et al., “Identiﬁcation
of cross-reactive antigenic target regions for HIV type 1-spe-
ciﬁc antibody-dependent cellular cytotoxicity,” AIDS Research
and Human Retroviruses, vol. 12, no. 18, pp. 1699–1702, 1996.
[67] D. S. Tyler, S. D. Stanley, S. Zolla-Pazner et al., “Identiﬁcation
of sites within gp41 that serve as targets for antibody-de-
pendent cellular cytotoxicity by using human monoclonal
antibodies,” Journal of Immunology, vol. 145, no. 10, pp. 3276–
3282, 1990.
[68] U.H.M.Ziegner,I.Frank,A.Bernatowicz,S.E.Starr,andH.J.
Streckert, “Antibody-dependent cellular cytotoxicity (ADCC)
is directed against immunodominant epitopes of the envelope
proteins of human immunodeﬁciency virus 1 (HIV-1),” Viral
Immunology, vol. 5, no. 4, pp. 273–281, 1992.
[69] M. Duval, M. R. Posner, and L. A. Cavacini, “A bispeciﬁc
antibody composed of a nonneutralizing antibody to the
gp41 immunodominant region and an anti-CD89 antibody
directs broad human immunodeﬁciency virus destruction by
neutrophils,” Journal of Virology, vol. 82, no. 9, pp. 4671–4674,
2008.8 Advances in Virology
[70] R.H.Florese,T .Demberg,P .Xiaoetal.,“Contributionofnon-
neutralizing vaccine-elicited antibody activities to improved
protective eﬃcacy in rhesus macaques immunized with Tat/
Env compared with multigenic vaccines,” Journal of Immunol-
ogy, vol. 182, no. 6, pp. 3718–3727, 2009.
[71] T.YamadaandA.Iwamoto,“ExpressionofanovelNefepitope
onthesurfaceofHIVtype1-infectedcells,”AIDSResearchand
Human Retroviruses, vol. 15, no. 11, pp. 1001–1009, 1999.
[72] T. Yamada, N. Watanabe, T. Nakamura, and A. Iwamoto,
“Antibody-dependent cellular cytotoxicity via humoral im-
mune epitope of nef protein expressed on cell surface,” Journal
of Immunology, vol. 172, no. 4, pp. 2401–2406, 2004.
[73] A. J. Hessell, L. Hangartner, M. Hunter et al., “Fc receptor but
not complement binding is important in antibody protection
against HIV,” Nature, vol. 449, no. 7158, pp. 101–104, 2007.
[74] V. R. G´ omez-Rom´ a n ,L .J .P a t t e r s o n ,D .V e n z o ne ta l . ,“ V a c -
cine-elicited antibodies mediate antibody-dependent cellular
cytotoxicity correlated with signiﬁcantly reduced acute vire-
mia in rhesus macaques challenged with SIVmac251,” Journal of
Immunology, vol. 174, no. 4, pp. 2185–2189, 2005.
[75] G. Isitman, A. W. Chung, M. Navis, S. J. Kent, and I. Stratov,
“Pol as a target for antibody dependent cellular cytotoxicity
responses in HIV-1 infection,” Virology, vol. 412, no. 1, pp.
110–116, 2011.
[76] I. Stratov, A. Chung, and S. J. Kent, “Robust NK cell-mediated
human immunodeﬁciency virus (HIV)-speciﬁc antibody-
dependent responses in HIV-infected subjects,” Journal of Vi-
rology, vol. 82, no. 11, pp. 5450–5459, 2008.
[77] G.Isitman,A.Chung,M.Navis,I.Stratov,andS.Kent,“ADCC
immunity to HIV-1 Pol,” in Proceedings of the Annual Confer-
ence of the Australasian Society for HIV Medicine (ASHM ’11),
Canberra, Australia, 2011.
[78] S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan et al., “Vacci-
nation with ALVAC and AIDSVAX to prevent HIV-1 infection
in Thailand,” New England Journal of Medicine, vol. 361, no.
23, pp. 2209–2220, 2009.
[79] B. Haynes, AIDS Vaccine, Bangkok, Thailand, 2011.
[80] V. Peut and S. J. Kent, “Substantial envelope-speciﬁc CD8 T-
cell immunity fails to control siv disease,” Virology, vol. 384,
no. 1, pp. 21–27, 2009.
[81] A. D. Kelleher, C. Long, E. C. Holmes et al., “Clustered mu-
tations in HIV-1 gag are consistently required for escape from
HLA-B27-restricted cytotoxic T lymphocyte responses,” Jour-
nal of Experimental Medicine, vol. 193, no. 3, pp. 375–385,
2001.
[82] L. L. Lanier, “Up on the tightrope: natural killer cell activation
andinhibition,”NatureImmunology,vol.9,no.5,pp.495–502,
2008.
[83] G. Alter, M. P. Martin, N. Teigen et al., “Diﬀerential natural
killer cell-mediated inhibition of HIV-1 replication based on
distinctKIR/HLAsubtypes,”JournalofExperimentalMedicine,
vol. 204, no. 12, pp. 3027–3036, 2007.
[84] M. P. Martin, X. Gao, J. H. Lee et al., “Epistatic interaction
between KIR3DS1 and HLA-B delays the progression to
AIDS,” Nature Genetics, vol. 31, no. 4, pp. 429–434, 2002.
[85] G. Alter, D. Heckerman, A. Schneidewind et al., “HIV-1 adap-
tation to NK-cell-mediated immune pressure,” Nature, vol.
476, no. 7358, pp. 96–101, 2011.